Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the safety, tolerability, and pharmacokinetics
(PK) of three different doses of an investigational medication, EVP-6124, in individuals with
mild to moderate Alzheimer's disease who are also taking an Alzheimer's medication (AChEI
[acetylcholinesterase inhibitor]: either donepezil or rivastigmine). In addition, PK of AChEI
medications will be assessed. Cognitive function will be evaluated on an exploratory basis.